期刊
ONCOTARGET
卷 6, 期 12, 页码 9766-9780出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2870
关键词
VEGFR-2; EMMPRIN/CD147; interaction/activation; coreceptor
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- La Ligue Nationale contre le Cancer (LNCC)
- La Societe Francaise de Dermatologie
- Universite Paris Diderot
- Canceropole-Ile de France
- Fondation ARC pour la Recherche sur le Cancer
- Spanish Ministry of Science
- Plan NacionalI+D+iMICINN [BIO2010-22324]
- Association Saint-Louis
- Ministere de la Recherche
- Conseil Regional d'Ile-de-France
EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据